辉瑞 PFE 深 沪
等待开盘 06-24 09:30:00 美东时间
24.72
-0.360
-1.44%
华盛通- 最 高25.235
- 今 开24.99
- 成交量 8199.32万股
- 最 低 24.69
- 昨 收 25.08
- 总市值 1408.90亿
- 52周最高 28.315
- 市盈率 静 18.23
- 换手率 1.44%
- 52周最低 21.82
- 委 比 -9.85%
- 总股本 56.99亿
- 历史最高 54.21
- 量 比 1.58
- 振 幅 2.17%
- 历史最低 -3.4773
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pfizer patent win against Enanta over COVID pill upheld by appeals court
A federal appeals court has sided with Pfizer (PFE) in a patent dispute with Enanta Pharmaceuticals (ENTA) over the pharma giant’s COVID-19 therapy Paxlovid. The Court of Appeals for the Federal Circu...
今天 00:29
'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg
https://news.bloomberglaw.com/us-law-week/pfizer-keeps-win-in-patent-lawsuit-aimed-at-paxlovid-antiviral
06-23 23:32
辉瑞PFE肺癌药物三期临床试验未达生存终点
辉瑞（PFE）宣布其在研晚期肺癌药物西格伏妥单抗 vedotin的关键III期临床试验，对比标准化疗药物多西他赛针对转移性非鳞状非小细胞肺癌患者，未能达成总生存...
06-23 22:42
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients
Pfizer Inc. (NYSE:PFE) on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug conjugate sigvotatug vedotin in previously treated advanced non-squamous non-small cell lung cancer (NSCLC). While the study missed its primary overall survival endpoint...
06-23 22:34
辉瑞肺癌疗法遇挫未伤根本 但其价值430亿美元的Seagen相关预期进一步降温
辉瑞SigVie-002三期临床未达主要终点：针对既往接受过治疗的转移性非鳞状非小细胞肺癌全受试人群，西伏妥珠单抗维多汀相比多西他赛未展现具有统计学意义的总生存...
06-23 21:39
A big battleship to turn: Evercore downgrades Nike to In-Line
Nearly two years since Elliott Hill took the helm at Nike (NKE), Evercore’s checks suggest the timeframe for a turnaround could get pushed out again, leading analyst Michael Binetti to downgrade the s...
06-23 21:26
Pfizer lung cancer therapy fails in late-stage trial versus chemotherapy
Pfizer (PFE) has announced a trial setback for a lung cancer therapy added through its $43B acquisition of Seagen in 2023, noting that its antibody-drug conjugate sigvotatug vedotin failed to outperfo...
06-23 19:00
辉瑞终止肥胖症药物押注 礼来仍在布局未来
核心事件：辉瑞终止在研口服GLP-1减重药物danuglipron项目，退出减重赛道，当前全球减重赛道仍有超80家核心企业推进超100款减重治疗在研产品。 关键...
06-23 08:07
礼来公司减肥药赛道溢价名副其实 辉瑞270亿美元押注表明行业竞赛尚未结束
当前美股减重药赛道呈现两类头部药企分化布局态势：礼来依托已验证的减重药产品线锁定当期现金流，成为首家市值破1万亿美元的制药企业，获得市场估值溢价；辉瑞则通过收购...
06-23 08:03
辉瑞股价重回200日均线以上 真正考验将于7月29日开启
核心事件：辉瑞（PFE）股价走势现积极信号，2026年7月29日即将发布的财报是验证当前反弹能否转化为可持续估值修复的核心关口，同时公司宣布CFO戴夫·丹顿8月...
06-23 04:52
公司简介
公司名称
|
辉瑞
|
行业分类
|
制药
|
业务描述
|
在辉瑞，我们致力于运用科学以及我们的全球资源来改善每个生命阶段的健康状况。在药品的探索、开发和生产过程中，我们多样化的全球保健产品包括生物药品、小分子药品和疫苗，以及许多世界驰名的健康药物。每天，世界各地的辉瑞员工致力于推进健康，以及能够应对我们这个时代最为棘手的疾病的预防和治疗方案。辉瑞还与世界各地的医疗卫生专业人士、政府和社区合作，支持世界各地的人们能够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家世界领先的生物制药公司的责任是一致的。160多年来，辉瑞一直努力为人们提供更好、更优质的服务。
2016年收入528亿美元，全球63个生产基地，业务遍布全球约175个国家和地区，有9种产品的销售额超过10亿美元，2016年新增140多个研发合作机构，全球96,500余名员工。
|
Pfizer patent win against Enanta over COVID pill upheld by appeals court
A federal appeals court has sided with Pfizer (PFE) in a patent dispute with Enanta Pharmaceuticals (ENTA) over the pharma giant’s COVID-19 therapy Paxlovid. The Court of Appeals for the Federal Circu...
今天 00:29
'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg
https://news.bloomberglaw.com/us-law-week/pfizer-keeps-win-in-patent-lawsuit-aimed-at-paxlovid-antiviral
06-23 23:32
辉瑞PFE肺癌药物三期临床试验未达生存终点
辉瑞（PFE）宣布其在研晚期肺癌药物西格伏妥单抗 vedotin的关键III期临床试验，对比标准化疗药物多西他赛针对转移性非鳞状非小细胞肺癌患者，未能达成总生存...
06-23 22:42
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients
Pfizer Inc. (NYSE:PFE) on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug conjugate sigvotatug vedotin in previously treated advanced non-squamous non-small cell lung cancer (NSCLC). While the study missed its primary overall survival endpoint...
06-23 22:34
辉瑞肺癌疗法遇挫未伤根本 但其价值430亿美元的Seagen相关预期进一步降温
辉瑞SigVie-002三期临床未达主要终点：针对既往接受过治疗的转移性非鳞状非小细胞肺癌全受试人群，西伏妥珠单抗维多汀相比多西他赛未展现具有统计学意义的总生存...
06-23 21:39
A big battleship to turn: Evercore downgrades Nike to In-Line
Nearly two years since Elliott Hill took the helm at Nike (NKE), Evercore’s checks suggest the timeframe for a turnaround could get pushed out again, leading analyst Michael Binetti to downgrade the s...
06-23 21:26
Pfizer lung cancer therapy fails in late-stage trial versus chemotherapy
Pfizer (PFE) has announced a trial setback for a lung cancer therapy added through its $43B acquisition of Seagen in 2023, noting that its antibody-drug conjugate sigvotatug vedotin failed to outperfo...
06-23 19:00
辉瑞终止肥胖症药物押注 礼来仍在布局未来
核心事件：辉瑞终止在研口服GLP-1减重药物danuglipron项目，退出减重赛道，当前全球减重赛道仍有超80家核心企业推进超100款减重治疗在研产品。 关键...
06-23 08:07
礼来公司减肥药赛道溢价名副其实 辉瑞270亿美元押注表明行业竞赛尚未结束
当前美股减重药赛道呈现两类头部药企分化布局态势：礼来依托已验证的减重药产品线锁定当期现金流，成为首家市值破1万亿美元的制药企业，获得市场估值溢价；辉瑞则通过收购...
06-23 08:03
辉瑞股价重回200日均线以上 真正考验将于7月29日开启
核心事件：辉瑞（PFE）股价走势现积极信号，2026年7月29日即将发布的财报是验证当前反弹能否转化为可持续估值修复的核心关口，同时公司宣布CFO戴夫·丹顿8月...
06-23 04:52
派息除权日
|
每股总股息
| 派息日期 |
2026-05-08
|
0.43
|
2026-06-12
|
2026-01-23
|
0.43
|
2026-03-06
|
2025-11-07
|
0.43
|
2025-12-01
|
2025-07-25
|
0.43
|
2025-09-02
|
2025-05-09
|
0.43
|
2025-06-13
|
2025-01-24
|
0.43
|
2025-03-07
|
2024-11-08
|
0.42
|
2024-12-02
|
2024-07-26
|
0.42
|
2024-09-03
|
2024-05-09
|
0.42
|
2024-06-14
|
2024-01-25
|
0.42
|
2024-03-01
|
2023-11-09
|
0.41
|
2023-12-04
|
2023-07-27
|
0.41
|
2023-09-05
|
2023-05-11
|
0.41
|
2023-06-09
|
2023-01-26
|
0.41
|
2023-03-03
|
2022-11-03
|
0.40
|
2022-12-05
|
2022-07-28
|
0.40
|
2022-09-06
|
2022-05-12
|
0.40
|
2022-06-10
|
2022-01-27
|
0.40
|
2022-03-04
|
2021-11-04
|
0.39
|
2021-12-06
|
2021-07-29
|
0.39
|
2021-09-07
|
2021-05-06
|
0.39
|
2021-06-04
|
2021-01-28
|
0.39
|
2021-03-05
|
2020-11-05
|
0.38
|
2020-12-01
|
2020-07-30
|
0.38
|
2020-09-01
|
2020-05-07
|
0.38
|
2020-06-05
|
2020-01-30
|
0.38
|
2020-03-06
|
2019-11-07
|
0.36
|
2019-12-02
|
2019-08-01
|
0.36
|
2019-09-03
|
2019-05-09
|
0.36
|
2019-06-07
|
2019-01-31
|
0.36
|
2019-03-01
|
2018-11-08
|
0.34
|
2018-12-03
|
2018-08-02
|
0.34
|
2018-09-04
|
2018-05-10
|
0.34
|
2018-06-01
|
2018-02-01
|
0.34
|
2018-03-01
|
2017-11-09
|
0.32
|
2017-12-01
|
2017-08-02
|
0.32
|
2017-09-01
|
2017-05-10
|
0.32
|
2017-06-01
|
2017-02-01
|
0.32
|
2017-03-01
|
2016-11-08
|
0.30
|
2016-12-01
|
2016-08-03
|
0.30
|
2016-09-01
|
2016-05-11
|
0.30
|
2016-06-01
|
2016-02-03
|
0.30
|
2016-03-02
|
2015-11-04
|
0.28
|
2015-12-01
|
2015-08-05
|
0.28
|
2015-09-02
|
2015-05-06
|
0.28
|
2015-06-02
|
2015-02-04
|
0.28
|
2015-03-03
|
2014-11-05
|
0.26
|
2014-12-02
|
2014-07-30
|
0.26
|
2014-09-03
|
2014-05-07
|
0.26
|
2014-06-03
|
2014-02-05
|
0.26
|
2014-03-04
|
2013-11-06
|
0.24
|
2013-12-03
|
2013-07-31
|
0.24
|
2013-09-04
|
2013-05-08
|
0.24
|
2013-06-04
|
2013-01-30
|
0.24
|
2013-03-05
|
2012-11-07
|
0.22
|
2012-12-04
|
2012-08-01
|
0.22
|
2012-09-05
|
2012-05-09
|
0.22
|
2012-06-05
|
2012-02-01
|
0.22
|
2012-03-06
|
2011-11-08
|
0.20
|
2011-12-06
|
2011-08-03
|
0.20
|
2011-09-06
|
2011-05-11
|
0.20
|
2011-06-07
|
2011-02-02
|
0.20
|
2011-03-01
|
2010-11-04
|
0.18
|
2010-12-01
|
2010-08-04
|
0.18
|
2010-09-01
|
2010-05-05
|
0.18
|
2010-06-01
|
2010-02-03
|
0.18
|
2010-03-02
|
2009-11-04
|
0.16
|
2009-12-01
|
2009-08-05
|
0.16
|
2009-09-02
|
2009-05-06
|
0.16
|
2009-06-02
|
2009-02-04
|
0.32
|
2009-03-03
|
2008-11-05
|
0.32
|
2008-12-02
|
2008-08-06
|
0.32
|
2008-09-03
|
2008-05-07
|
0.32
|
2008-06-03
|
2008-02-06
|
0.32
|
2008-03-04
|
2007-11-07
|
0.29
|
2007-12-04
|
2007-08-08
|
0.29
|
2007-09-05
|
2007-05-09
|
0.29
|
2007-06-05
|
2007-02-07
|
0.29
|
2007-03-06
|
2006-11-08
|
0.24
|
2006-12-05
|
2006-08-09
|
0.24
|
2006-09-05
|
2006-05-10
|
0.24
|
2006-06-06
|
2006-02-08
|
0.24
|
2006-03-07
|
2005-11-08
|
0.19
|
2005-12-06
|
2005-08-10
|
0.19
|
2005-09-06
|
2005-05-11
|
0.19
|
2005-06-07
|
2005-02-09
|
0.19
|
2005-03-08
|
2004-11-09
|
0.17
|
2004-12-03
|
2004-08-11
|
0.17
|
2004-09-03
|
2004-05-12
|
0.17
|
2004-06-04
|
2004-02-11
|
0.17
|
2004-03-05
|
2003-11-12
|
0.15
|
2003-12-04
|
2003-08-13
|
0.15
|
2003-09-04
|
2003-05-14
|
0.15
|
2003-06-05
|
2003-01-15
|
0.15
|
2003-02-14
|
2002-11-13
|
0.13
|
2002-12-05
|
2002-08-14
|
0.13
|
2002-09-05
|
2002-05-15
|
0.13
|
2002-06-06
|
2002-02-13
|
0.13
|
2002-03-07
|
2001-11-14
|
0.11
|
2001-12-06
|
2001-08-15
|
0.11
|
2001-09-06
|
2001-05-16
|
0.11
|
2001-06-07
|
2001-02-14
|
0.11
|
2001-03-08
|
2000-11-15
|
0.09
|
2000-12-07
|
2000-08-16
|
0.09
|
2000-09-07
|
2000-05-09
|
0.09
|
2000-06-08
|
2000-02-16
|
0.09
|
2000-03-09
|
1999-11-09
|
0.08
|
1999-12-09
|
1999-08-04
|
0.08
|
1999-09-09
|
1999-05-05
|
0.22
|
1999-06-10
|
1999-02-10
|
0.22
|
1999-03-11
|
1998-11-04
|
0.19
|
1998-12-10
|
1998-08-05
|
0.19
|
1998-09-10
|
1998-05-06
|
0.19
|
1998-06-11
|
1998-02-04
|
0.19
|
1998-03-12
|
1997-11-05
|
0.17
|
1997-12-11
|
1997-07-30
|
0.17
|
1997-09-11
|
1997-05-07
|
0.34
|
1997-06-12
|
1997-02-05
|
0.34
|
1997-03-13
|
1996-11-06
|
0.30
|
1996-12-12
|
1996-07-31
|
0.30
|
1996-09-12
|
1996-05-08
|
0.30
|
1996-06-13
|
1996-02-07
|
0.30
|
1996-03-14
|
1995-11-08
|
0.26
|
1995-12-21
|
1995-08-02
|
0.26
|
1995-09-21
|
1995-05-08
|
0.52
|
1995-06-15
|
1995-02-06
|
0.52
|
1995-03-16
|
1994-11-04
|
0.47
|
1994-12-15
|
1994-08-01
|
0.47
|
1994-09-15
|
1994-05-09
|
0.47
|
1994-06-16
|
1994-02-07
|
0.47
|
1994-03-17
|
1993-11-05
|
0.42
|
1993-12-16
|
1993-08-02
|
0.42
|
1993-09-16
|
1993-05-10
|
0.42
|
1993-06-17
|
1993-02-08
|
0.42
|
1993-03-18
|
1992-11-16
|
0.37
|
1992-12-17
|
1992-08-03
|
0.37
|
1992-09-17
|
1992-05-11
|
0.37
|
1992-06-18
|
1992-02-03
|
0.37
|
1992-03-19
|
1991-11-08
|
0.33
|
1991-12-19
|
1991-08-01
|
0.33
|
1991-09-19
|
1991-05-13
|
0.33
|
1991-06-20
|
1991-02-22
|
0.66
|
1991-03-21
|
1990-11-09
|
0.60
|
1990-12-20
|
1990-08-06
|
0.60
|
1990-09-20
|
1990-05-14
|
0.60
|
1990-06-21
|
1990-02-05
|
0.60
|
1990-03-22
|
1989-11-13
|
0.55
|
1989-12-21
|
1989-07-24
|
0.55
|
1989-09-21
|
1989-05-15
|
0.55
|
1989-06-21
|
1989-01-23
|
0.55
|
1989-03-22
|
1988-11-15
|
0.50
|
1988-12-20
|
1988-07-25
|
0.50
|
1988-09-20
|
1988-05-16
|
0.50
|
1988-06-20
|
1988-02-12
|
0.50
|
1988-03-21
|
1987-11-16
|
0.45
|
1987-12-21
|
1987-07-27
|
0.45
|
1987-09-21
|
1987-05-14
|
0.45
|
1987-06-19
|
1987-01-26
|
0.45
|
1987-03-20
|
1986-11-17
|
0.41
|
1986-12-19
|
1986-07-28
|
0.41
|
1986-09-19
|
1986-05-14
|
0.41
|
1986-06-20
|
1986-01-27
|
0.41
|
1986-03-21
|
1985-11-15
|
0.37
|
1985-12-20
|
1985-07-26
|
0.37
|
1985-09-20
|
1985-05-20
|
0.37
|
1985-06-21
|
1985-01-28
|
0.37
|
1985-03-21
|
1984-11-13
|
0.33
|
1984-12-20
|
1984-07-26
|
0.33
|
1984-09-20
|
1984-05-14
|
0.33
|
1984-06-21
|
1984-01-26
|
0.33
|
1984-03-21
|
1983-11-14
|
0.29
|
1983-12-21
|
1983-07-26
|
0.29
|
1983-09-21
|
1983-05-13
|
0.58
|
1983-06-21
|
1983-01-26
|
0.58
|
1983-03-21
|
1982-11-15
|
0.46
|
1982-12-21
|
1982-07-27
|
0.46
|
1982-09-21
|
1982-05-13
|
0.46
|
1982-06-21
|
1982-01-26
|
0.46
|
1982-03-19
|
1981-11-13
|
0.40
|
1981-12-21
|
1981-08-13
|
0.40
|
1981-09-21
|
1981-05-13
|
0.40
|
1981-06-19
|
1981-02-11
|
0.40
|
1981-03-20
|
1980-11-28
|
0.36
|
1980-12-22
|
1980-09-02
|
0.36
|
1980-09-29
|
1980-05-29
|
0.36
|
1980-06-27
|
1980-03-03
|
0.36
|
1980-03-30
|
1979-11-22
|
0.33
|
1979-12-18
|
1979-08-27
|
0.33
|
1979-09-20
|
1979-05-23
|
0.33
|
1979-06-21
|
1979-03-05
|
0.33
|
1979-03-29
|
1978-11-21
|
0.30
|
1978-12-17
|
1978-08-28
|
0.30
|
1978-09-21
|
1978-05-25
|
0.30
|
1978-06-22
|
1978-02-27
|
0.27
|
1978-03-23
|
1977-11-24
|
0.27
|
1977-12-18
|
1977-09-01
|
0.24
|
1977-09-22
|
1977-05-30
|
0.24
|
1977-06-23
|
1977-02-28
|
0.24
|
1977-03-24
|
